Researchers developed NeoPAIR-T, a CRISPR-engineered reporter system that efficiently identifies which cancer-specific peptide fragments are recognized by which T cell receptors, successfully finding two functional pairs from lung cancer samples.
2 functional neoantigen-TCR pairs identifiedOut of 63 candidate peptides and 8 TCR clonotypes from lung cancer samples, validated with EC50 values in the nanomolar to micromolar range
What the researchers found
NeoPAIR-T successfully identified two functional neoantigen-TCR pairs from lung cancer samples out of 63 candidate peptides and 8 TCR clonotypes. The system uses CRISPR-engineered Jurkat reporter T cells with luciferase/eGFP dual readout and autologous antigen-presenting cells transfected with tandem minigenes encoding predicted neoantigens. The validated pairs showed functional binding with EC50 values ranging from 10⁻⁹·² to 10⁻⁶·⁷ M, confirmed by peptide assays. Key innovations include TCRα-knockout with targeted knock-in to prevent receptor mispairing, and the ability to test multiple reporter clones in parallel against the same antigen-presenting cells.
Why it matters
Personalized cancer vaccines and adoptive T cell therapies need to know exactly which mutant peptides a patient's immune system can target, but current methods are slow, expensive, and unreliable. NeoPAIR-T offers a streamlined approach that could accelerate the development of personalized immunotherapies by making neoantigen-TCR matching more efficient and scalable.
The numbers in context
63 candidate neoantigen peptides · 3 tandem minigenes · 8 TCR clonotypes · 2 functional neoantigen-TCR pairs · EC50: 10⁻⁹·² to 10⁻⁶·⁷ M
How the study worked
The researchers engineered Jurkat T cells with a dual luciferase/eGFP reporter system that activates when the T cell receptor is triggered. They used CRISPR to knock out the native TCR alpha chain and knock in candidate TCRs at a specific location to prevent mispairing. Candidate neoantigen peptides were predicted from whole-exome and RNA sequencing of lung cancer samples, then assembled into tandem minigene constructs expressed in immortalized autologous antigen-presenting cells. Multiple reporter T cell clones were co-cultured with antigen-presenting cells in parallel to identify functional matches, which were then validated using individual peptide assays.
Who was studied
Lung cancer patient samples used for neoantigen-TCR pair discovery
What this study cannot tell us
The study demonstrated the system using samples from a single lung cancer case, so broader applicability across cancer types and patient populations is not yet established. The approach still depends on computational prediction of candidate neoantigens, which has inherent uncertainty. Only 2 of 63 candidates were confirmed as functional pairs, reflecting the known difficulty of neoantigen prediction rather than a limitation of the assay itself.
How to read the evidence
This is a proof-of-concept laboratory study demonstrating a new assay platform. While it successfully identified functional peptide-receptor pairs, it was validated using samples from a single cancer case and has not yet been tested in clinical applications.
When this study was published
Published in 2025, this represents current state-of-the-art work in the rapidly evolving field of neoantigen-targeted immunotherapy technology.
The bigger picture
Neoantigen-targeted immunotherapy — including personalized cancer vaccines and engineered T cell therapies — is one of the most promising frontiers in oncology, but has been bottlenecked by the difficulty of identifying which mutant peptides actually trigger immune responses. Tools like NeoPAIR-T could help break through this bottleneck by providing reliable, scalable functional validation of peptide-receptor pairs.
Questions still open
- Can NeoPAIR-T scale to high-throughput screening across multiple patients and cancer types in a clinical workflow?
- Would the neoantigen-TCR pairs identified by this system translate into effective therapeutic responses in actual patients?
- How does the sensitivity and specificity of NeoPAIR-T compare to existing neoantigen identification platforms?
Common questions
What is a neoantigen and why is it important for cancer treatment?
How does NeoPAIR-T improve on existing methods for matching neoantigens to T cell receptors?
Read the original research
NeoPAIR-T: Functional Mapping of Neoantigen-TCR Pairs Using a CRISPR-Engineered Jurkat Reporter System.
Cells, 14(22)
Citation
Nagaoka, Koji; Kobayashi, Yukari; Kakimi, Kazuhiro. (2025). NeoPAIR-T: Functional Mapping of Neoantigen-TCR Pairs Using a CRISPR-Engineered Jurkat Reporter System.. Cells, 14(22). https://doi.org/10.3390/cells14221789